Time for a change in breast cancer therapy?

Research output: Contribution to journalArticlepeer-review


Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.
Original languageEnglish
Pages (from-to)724-9
Number of pages6
JournalHospital medicine
Issue number12
Publication statusPublished - Dec 2004


  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Female
  • Forecasting
  • Humans
  • Postmenopause
  • Treatment Outcome


Dive into the research topics of 'Time for a change in breast cancer therapy?'. Together they form a unique fingerprint.

Cite this